Key Takeaways: High-risk localized prostate cancer has higher chances of recurrence and progression compared to low/intermediate risk.
Androgen deprivation therapy (ADT) reduces tumor size but shows no survival benefit.
Second-generation agents (like ARPIs) are showing promise in improving survival outcomes in trials.
Highlights from the Review:
- Guideline Status: Neoadjuvant therapy is not yet standard care, recommended only within clinical trials.
- Promising Trials: Phase II studies suggest better pathological outcomes and lower relapse rates with ADT + ARPIs.
- Future Directions: Innovative therapies like Lu-177 PSMA and genomics-based treatments hold potential for personalized care.
What’s Next?: More robust Phase III trials are needed to solidify these therapies as game-changers!
For clinicians and researchers: The focus remains on improving biomarkers and identifying patients who will benefit most.”